Biography

Michael Veve, PharmD, MPH, is a Clinical Associate Professor in the Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University.  He practices as a Clinical Pharmacy Specialist in Infectious Diseases at Henry Ford Hospital in Detroit, where he is involved in antimicrobial stewardship patient care.  Dr. Veve is the outcomes pharmacotherapy fellowship director, which is a two-year program jointly funded through EACPHS and Henry Ford Hospital (see: https://www.henryford.com/hcp/med-ed/allied/pharmacy/id-fellowship). 

Degrees and Certifications

• 2020 - Master of Public Health, Wayne State University School of Medicine, Detroit, MI
• 2017 - Fellowship in Infectious Diseases Outcomes Research, Henry Ford Hospital/Wayne State University, Detroit, MI
• 2015 - Pharmacy Practice Residency, Henry Ford Hospital, Detroit, MI
• 2014 - Doctor of Pharmacy, Albany College of Pharmacy and Health Sciences, Albany, NY

Positions and Employment

• 2020-Present - Clinical Assistant Professor, Wayne State University, College of Pharmacy, Detroit, MI
• 2020-Present - Clinical Pharmacy Specialist, Infectious Diseases, Henry Ford Health System, Detroit, MI
• 2017–2020- Clinical Assistant Professor, University of Tennessee Health Science Center, College of Pharmacy, Knoxville, TN

Awards and Honors

• 2024 - Preceptor of the Year, 2023-2024; College of Pharmacy and Health Sciences, Wayne State University
• 2019 - Professor of the Year, 2018-2019, University of Tennessee Health Science Center College of Pharmacy

Professional Memberships

• 2020 – 2022: American Public Health Association
• 2018 – 2020: Tennessee Department of Health, Multi-Disciplinary Advisory Group on Healthcare Associated Infections
• 2018 – 2020: Infectious Diseases Educator Network
• 2018 – 2020: Tennessee Pharmacists Association
• 2017 – Present: American Association of Colleges of Pharmacy
• 2017 – 2019: The Society for Healthcare Epidemiology of America
• 2016 – 2017: Infectious Diseases Society of America
• 2015 – Present: Making a Difference in Infectious Diseases (MAD-ID) Research Network
• 2015 – Present: Society of Infectious Diseases Pharmacists, Associate member
• 2014 – 2020: American College of Clinical Pharmacy
• 2014 – 2017: American Society for Microbiology
• 2014 – 2017: Michigan Society of Health-System Pharmacists
• 2013 – 2016: American Society of Health-System Pharmacists
• 2009 – 2014: Northeastern New York Society of Hospital Pharmacists

Areas of Expertise

• Antimicrobial stewardship
• Public Health practice

Primary Research Interest

• Implementation and assessment of novel antimicrobial stewardship interventions
• Epidemilogy and outcomes of multi-drug resistant pathogens
• Antimicrobial optimization in specialized patient populations
• Prevention and treatment optimization of infections due to injection-drug use 

Recent Publications

Chapters Published

• Veve MP. Chapter-33. Infectious Diseases. In: Chyka PA, Franks AS, Waddell JA, Boucher BA, eds. The APhA Complete Review for Pharmacy, 13th ed. Washington, DC: American Pharmacists Association. 2022.

• Veve MP. Chapter 34: Anti-infective agents. In: Chyka PA, Franks AS, Waddell JA, Boucher BA, eds. The APhA Complete Review for Pharmacy, 13th ed. Washington, DC: American Pharmacists Association. 2022.

Co-Authored

• Mercuro NJ and Veve MP. Evaluating and reporting antimicrobial-related harms. Infectious Diseases Self-Assessment Program (IDSAP). American College of Clinical Pharmacy. 2022.

• Veve MP and Athans V. Chapter 31 Vaccines. In: Ray SD, editor. Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions. Vol 41; Elsevier; 2019.

• Veve MP and Athans V. Interactive Case: Antimicrobial stewardship in critical care. Critical Case. Critical Care Self-Assessment Program (CCSAP). American College of Clinical Pharmacy. 2019.

• Veve MP and Athans V. Chapter 31 Vaccines. In: Ray SD, editor. Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions. Vol 40; Elsevier; 2018. p. 383-413.

Refereed Journals

• Arena CJ, Kenney RM, Eriksson E, Brar I, Veve MP. Prescribing Practices of Recommended Treatment for Trichomonas vaginalis and Chlamydia trachomatis after 2021 STI Treatment Guideline Update. Sex Transm Dis. Published online May 6, 2024. doi:10.1097/OLQ.0000000000001987

• Vandervelde R, Mlynarek ME, Ramesh M, Patel N, Veve MP, August BA. Impact of time to treatment in first occurrence, non-severe Clostridioides difficile infection for elderly patients: are we waiting too long to treat?. Antimicrob Steward Healthc Epidemiol. 2024;4(1):e59. Published 2024 Apr 24. doi:10.1017/ash.2024.46

• Cady EA, Dillon AJ, Bourland K, Rybakov I, Cluck DB, Veve MP. You'll have to call the attending: Impact of a longitudinal, "real-time" case-based infectious diseases elective on entrustable professional activities to enhance APPE readiness. Curr Pharm Teach Learn. Published online April 26, 2024. doi:10.1016/j.cptl.2024.04.008

• Rebold N, Alosaimy S, Pearson JC, Dionne B, Taqi A, Lagnf A, Lucas K, Biagi M, Lombardo N, Eudy J, Anderson DT, Mahoney MV, Kufel WD, D'Antonio JA, Jones BM, Frens JJ, Baumeister T, Geriak M, Sakoulas G, Farmakiotis D, Delaportas D, Larew J, Veve MP, Rybak MJ. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study. Infect Dis Ther. 2024 Mar;13(3):565-579. doi: 10.1007/s40121-024-00933-2. Epub 2024 Mar 1. PMID: 38427289; PMCID: PMC10965835.

• El Ghali A, Kunz Coyne AJ, Lucas K, Tieman M, Xhemali X, Lau S-p, Iturralde G, Purdy A, Holger DJ, Garcia E, Veve MP, Rybak MJ. Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections. Microbiol Spectr. 2024 Feb 6;12(2):e0310823. doi: 10.1128/spectrum.03108-23. Epub 2024 Jan 11. PMID: 38206034; PMCID: PMC10846278.

• Kunz Coyne AJ, Alosaimy S, Lucas K, Lagnf AM, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, Kang-Birken SL, Hobbs AL, Agee J, Perkins NB 3rd, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, Claeys KC, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Scipione MR, Zhao JJ, Witucki P, Rybak MJ. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr. 2024 Jan 11;12(1):e0235123. doi: 10.1128/spectrum.02351-23. Epub 2023 Nov 29. PMID: 38018984; PMCID: PMC10782980.

• Shallal A, Jarrah J, Prentiss T, Suleyman G, Veve MP, Banat A, Zervos J, Mousa AB, Msadeh L, Zerriouh Thneibat FM, Zervos M, Al-Raiby J, Alsawalha L, Zayed B. Lessons from the field: Supporting infection prevention and control and antimicrobial stewardship in Amman, Jordan. J Infect Public Health. 2023 Dec;16 Suppl 1:78-81. doi: 10.1016/j.jiph.2023.10.044. Epub 2023 Nov 2. PMID: 37945495.

• Hardy ME, Kenney RM, Tibbetts RJ, Shallal AB, Veve MP. Leveraging stewardship to promote ceftriaxone use in severe infections with low- and no-risk AmpC Enterobacterales. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0082623. doi: 10.1128/aac.00826-23. Epub 2023 Oct 26. PMID: 37882541; PMCID: PMC10649093.

• Kunz Coyne AJ, Orzol C, Veve MP, Rybak MJ. Weighing the odds: novel β-Lactam/βlactamase inhibitor use in hospital-acquired and ventilator-associated Pseudomonas aeruginosa pneumonia for patients who are morbidly obese. Open Forum Infect Dis. 2023 Aug 28;10(9):ofad454. doi: 10.1093/ofid/ofad454.

• Ho TA, Patterson KM, Gadgeel SM, Kenney RM, Veve MP. Cancer is chronic but antimicrobial stewardship is iconic: A retrospective cohort of optimal antibiotic use in ambulatory oncology clinics. Antimicrobial Stewardship & Healthcare Epidemiology (2023), 1–5.

• Vuong L, Kenney RM, Thomson JM, Faison DJ, Church BM, McCollom R, Gunaga S, Cahill MM, Slezak MA, Davis SL, Veve MP. Implementation of indication-based antibiotic order sentences improves antibiotic use in emergency departments. Am J Emerg Med. 2023 Mar 29;69:5-10.

• de Oca JEM, Veve MP, Zervos MJ, Kenney RM. Aminopenicillins versus Nonaminopenicillins for Treatment of Enterococcal Lower Urinary Tract Infections. Int J Antimicrob Agents. 2023 Mar 31:106800.

• Kunz Coyne AJ, El Ghali A, Lucas K, Witucki P, Rebold N, Holger DJ, Veve MP, Rybak MJ. High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production. Open Forum Infect Dis. 2023 Jan 25;10(3):ofad034.

• Arena CJ, Kenney RM, Kendall RE, Tibbetts RJ, Veve MP. Respiratory culture nudge improves antibiotic prescribing for Moraxella catarrhalis and Haemophilus influenzae lower respiratory tract infections. Antimicrob Steward Healthc Epidemiol. 2023 Feb 2;3(1):e23.

• Rebold N, Lagnf AM, Alosaimy S, Holger DJ, Witucki P, Mannino A, Dierker M, Lucas K, Kunz Coyne AJ, El Ghali A, Caniff KE, Veve MP, Rybak MJ. Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure. Microbiol Spectr. 2023 Feb 14;11(1):e0264722.

• Alosaimy S, Morrisette T, Lagnf AM, Rojas LM, King MA, Pullinger BM, Hobbs ALV, Perkins NB, Veve MP, Bouchard J, Gore T, Jones B, Truong J, Andrade J, Huang G, Cosimi R, Kang-Birken SL, Molina KC, Biagi M, Pierce M, Scipione MR, Zhao JJ, Davis SL, Rybak MJ. Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii. Microbiol Spectr. 2022 Oct 26;10(5):e0047922.

• Holger DJ, Rebold NS, Alosaimy S, Morrisette T, Lagnf A, Belza AC, Coyne AJK, El Ghali A, Veve MP, Rybak MJ. Impact of Ceftolozane-Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively DrugResistant Pseudomonas aeruginosa Lower Respiratory Tract Infections. Infect Dis Ther. 2022 Oct;11(5):1965-1980.

• Alosaimy S, Lagnf AM, Hobbs ALV, Mubarez M, Kufel WD, Morrisette T, Polisetty RS, Li D, Veve MP, Simon SP, Truong J, Finch N, Venugopalan V, Rico M, Amaya L, Yost C, Cubillos A, Chandler E, Patch M, Smith IMK, Biagi M, Wrin J, Moore WJ, Molina KC, Rebold N, Holger D, Kunz Coyne AJ, Jorgensen SCJ, Witucki P, Tran NN, Davis SL, Sakoulas G, Rybak MJ. Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam. Clin Infect Dis. 2023 Feb 8;76(3):e1444-e1455.

• Veve MP, Mercuro NJ, Sangiovanni RJ, Santarossa M, Patel N. Prevalence and Predictors of Pseudomonas aeruginosa Among Hospitalized Patients With Diabetic Foot Infections. Open Forum Infect Dis. 2022 Jun 17;9(7):ofac297.

• Morrisette T, Alosaimy S, Lagnf AM, Frens JJ, Webb AJ, Veve MP, Stevens R, Bouchard J, Gore TW, Ansari I, Rybak MJ. Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens. Infect Dis Ther. 2022 Aug;11(4):1715-1723.

• Walton MN, Hamilton LA, Kennedy S, Veve MP, Rowe AS. Incidence of infection and antimicrobial prophylaxis duration for external ventricular drains and intracranial pressure monitors. Surg Infect (Larchmt). 2022 Feb 8. doi: 10.1089/sur.2021.310. Epub ahead of
  print.

• Zasowski EJ, TrinhTD, Claeys KC, LagnfAM, Bhatia S, KlinkerKP, Veve MP, Estrada SJ, JohnsS, Sawyer AJ, Huang V, LaFrance B, Levine DP, Kaye KS, Davis SL, Rybak MJ. Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillinresistant Staphylococcus aureus bloodstream infection. Open Forum Infect Dis. 2021 Dec 23;9(3):ofab606.

• Kelly MC, Yeager SD, Shorman MA, Wright LR, Veve MP. Incidence and predictors of Gram-negative infections in hospitalized people who inject drugs with injection drug useattributable infections. Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0092521.

• Cernasev A, Veve MP, Summers NA, Hohmeier KC, Kumar S. Importance of PharmacistPatient Relationships in People Living with HIV and Opioid Use Disorder. Exploratory Research in Clinical and Social Pharmacy. 2021. 3. 100052. 10.1016/j.rcsop.2021.100052.

• Alosaimy S, Lagnf AM, Morrisette T, Scipione MR, Zhao JJ, Jorgensen SCJ, Mynatt R, Carlson TJ, Jo J, Garey KW, Allen D, DeRonde K, Vega A, Abbo LM, Venugopalan V, Athans V, Saw S, Claeys KC, Miller M, Veve MP, Kufel WD, Amaya L, Yost C, Ortwine J, Davis SL, Rybak MJ. Real-world multi-center experience with meropenem-vaborbactam for multidrug-resistant Gram-negative bacterial infections. Open Forum Infect Dis. 2021 Jul 14;8(8):ofab371. doi: 10.1093/ofid/ofab371.

• Cernasev A, Frederick KD, Hall EA, Veve MP, Hohmeier KC. “Don’t label them as addicts!” Student pharmacists’ views on the stigma associated with opioid use disorder. Innov Pharm. 2021 Jun 10;12(2):10.24926/iip.v12i2.3388.

• Yeager SD, Oliver JE, Shorman MA, Wright LR, Veve MP. Comparison of linezolid stepdown therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections. Accepted for publication at Inter J Antimicrob Agents. 2021. In
  press.

• Cernasev A, Kodidela S, Veve MP, Cory TJ, Jasmin H, Kumar S. A narrative systematic literature review: a focus on qualitative studies on HIV and medication assisted therapy in the United States. Accepted for publication at Pharmacy. 2021. In press.

• Morrisette T, Alosaimy S, Philley JV, Sigler C, Howard C, Webb AJ, Veve MP, Barger ML, Bouchard J, Gore TW, Lagnf AM, Ansari I, Mejia-Chew C, Cohen KA, Rybak MJ. Preliminary, real-world, multi-center experience with omadacycline for Mycobacterium
  abscessus infections. Open Forum Infect Dis. 2021. Epub ahead of print.

• Cernasev A, Veve MP, Talbott T, Hall EA, Hohmeier KC. Student pharmacists’ perceptions and stigma surrounding naloxone use in patients with opioid use disorder: a mixed methods evaluation. Pharmacy (Basel). 2020 Nov;8, 205.

• Veve MP, Akhtar Y, McKeown PP, Morelli MK, Shorman MA. Percutaneous mechanical aspiration vs valve surgery for tricuspid-valve endocarditis in people who inject drugs. Ann Thorac Surg. 2020 Oct 20:S0003-4975(20)31720-3. Epub ahead of print

• Morelli MK, Veve MP, Lorson W, Shorman MA. Candida spp. infective endocarditis: characteristics and outcomes of twenty cases with a focus on injection drug use as a predisposing risk factor. Mycoses. 2020 Oct 18. doi: 10.1111/myc.13200. Epub ahead of print.

• Veve MP, Patel N, Smith ZA, Yeager SD, Wright LR, Shorman MA. Comparison of dalbavancin to standard of care for outpatient treatment of invasive Gram-positive infections. Inter J Antimicrob Agents. 2020 Oct 23:106210. Epub ahead of print.

• Cooksey GE, Moye RA, Epps JL, Patel N, Shorman MA, Veve MP. Impact of a plan of care protocol on patient outcomes in people who inject drugs with infective endocarditis. J Infect Dis. 2020 Sep 2;222(Supplement_5):S506-S512.

• Cernasev A, Veve MP, Cory TJ, Summers NA, Miller M, Kodidela S, Kumar S. Opioid use disorders in people living with HIV/AIDS: a review of implications for patient outcomes, drug interactions, and neurocognitive disorders. Pharmacy (Basel). 2020 Sep 11;8(3):E168.

• Hall E, Cernasev A, Nastritdinova U, Veve MP, Hohmeier K. Student pharmacist perceptions of opioid use and stigma. Pharmacy (Basel). 2020 Aug 14;8(3):E144.

• Mercuro NJ, Veve MP. Clinical utility of lefamulin: if not now, when? Curr Infect Dis Rep. 2020;22(9):25.

• Morelli MK, Veve MP, Shorman MA. Maternal bacteremia caused by Staphylococcus aureus with a focus on infective endocarditis. Open Forum Infect Dis. 2020 Jun 19;7(8):ofaa239

• Veve MP, McCurry ED, Cooksey GE, Shorman MA. Epidemiology and outcomes of NonHACEK infective endocarditis in the southeast United States. PLOS One. 2020 Mar 10;15(3):e0230199.

• Alosaimy S, Jorgensen SCJ, Lagnf Am, Melvin S, Mynatt RP, Carlson TJ, Garey KW, Allen D, Venugopalan V, Veve M, Athans V, Saw S, Yost CN, Davis SL, Rybak MJ. Real-world multicenter analysis of clinical outcomes and safety of meropenemvaborbactam in patients treated for serious Gram-negative bacterial infections. Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa051

• Jorgensen SCJ, Murray KP, Lagnf AM, Melvin S, Bhatia S, Shamim MD, Smith JR, Brade KD, Simon S, Nagel J, Williams K, Ortwine J, Veve MP, Truong J, Davis SL, Rybak MJ. A multicenter evaluation of vancomycin-associated acute kidney injury in hospitalized
  patients with acute bacterial skin and skin structure infections. Infect Dis Ther. 2020 Mar;9(1):89-106.

• Lorson W, Veve MP, Heidel E, Shorman MA. The role of troponin as a predictor of inpatient mortality in infective endocarditis. BMC Infect Dis. 2020 Jan 8;20(1):24.

• Pogue JM, Kaye KS, Veve MP, Gerlach A, Patel TS, Davis SL, Dhar S, Puzniak L, File TM, Bonomo RA, Perez F. Real world treatment of multi-drug resistant (MDR) or extensively-drug resistant (XDR) P. aeruginosa infections with ceftolozane/tazobactam (C/T) versus a polymyxin or aminoglycoside (Poly/AG) based regimen: a multicenter comparative effectiveness study. Clin Infect Dis. 2020;71(2):304-310.

Non-Refereed Journals

• Arena CJ, Veve MP. Antibiotic Overprescribing in Sinusitis: Opportunities for Antimicrobial Stewardship? Michigan Society of Health System Pharmacists Monitor. 2024.

• Pearson SCS, Veve MP. Restructuring the Residency Research Experience. Pulses. 2021.

• Wagner JL, Veve MP, Barber KE. Use of an IL-6 inhibitor has the potential to prevent the cytokine storm caused by severe COVID-19 infection. Contagion Live. 2020.

Abstracts Published in Academic Journals

• Arena CJ, Kenney RM, Angster K, Shallal A, Davis SL, Veve MP. Malignant otitis externa: microbiology and implications on antimicrobial treatment. Abstract #P0990 at the 2024 ECCMID. Barcelona, Spain.

• Arena CJ, Kenney RM, Shallal A, Suleyman G, Davis SL, Veve MP. Comparison of trough vs point estimate area-under-curve vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia in the midwest United States. Abstract #P0927 at the 2024 ECCMID. Barcelona, Spain.

• Arena CJ, Kenney RM, Perkins N, Vincent S, Ramesh M, Davis SL, Veve MP. Adjunctive eravacycline as treatment in severe and fulminant Clostridioides difficile infections. Abstract #P3410 at the 2024 ECCMID. Barcelona, Spain.

• Caniff K, Peitsch C, Al Musawa M, Shupp M, Veve M, Alangaden G, Walsh T, Rybak MJ. Opening the DOOR to Candidemia Diagnostics: A Desirability of Outcomes Ranking Analysis of T2Candida vs. Blood Culture in Critically Ill Patients. Abstract #P3108 at the 2024 ECCMID. Barcelona, Spain.

• August B, Gutenschwager D, Griebe K, Swiderik J, Veve M, Smith Z. Proning in Acute Respiratory Distress Syndrome: To Paralyze or Not to Paralyze, That's the Question. Abstract #1167 at the 2024 SCCM Conference. Phoenix, Arizona.

• Kantharia S, Veve M, Mulugeta S, Beaulac A, Vincent S, Patel N. Impact of methicillinresistant Staphylococcus aureus nasal PCR on vancomycin use in pneumonia. Abstract #522 at the 2024 SCCM Conference. Phoenix, Arizona.

• Parke DM, Kenney RM, Bogojevich J, El-khoury C, Joshi S, Brar S, MacDonald L, Salib C, MacDonald N, Veve M, Suleyman G. Barriers to Improving Outcomes among People Experiencing Homelessness and People Who Inject Drugs Hospitalized for Complicated Infections. Abstract #1856 at IDWeek 2023. Boston, MA.

• El Ghali A, Kunze Coyne A, Lucas K, Tieman M, Purdy A, Iturralde G, Garcia E, Holger D, Lau S, Xhemali X, Veve MP, Rybak MJ. Comparative Analysis of Cefiderocol Monoand Combination Therapy for Multi-Drug Resistant Gram-negative Infections. Abstract #2118 at IDWeek 2023. Boston, MA.

• Kunze Coyne AJ, Lucas K, Shald E, Cabanilla MG, Yost C, VanDorf S, Slaton C, Kufel WD, Truong K, Andrade JA, Cerenzio J, Biagi M, Todd M, White B, Sassine J, Hayes JE, Witucki P, Orzol J, Eshaya M, Bleick C, Caniff KE, Veve MP, Rybak MJ. Early Administration of Ceftazidime-Avibactam for Carbapenem-Resistant Enterobacterales Is Associated with Improved Clinical Success. Abstract #2779 at IDWeek 2023. Boston, MA.

• Birk NK, Soman S, Kapur N, Pochhareddy V, Dillon WP, Veve M, Samuel L, Ramesh M, Alangaden GA. Candidemia: Role of T2Candida® compared to Bact/Alert Virtuo blood culture system in a real-world setting. Abstract #607 at IDWeek 2023. Boston, MA.

• Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Cifuentes R, Claeys KC, DeSear K, Gallagher JC, Gregory E, Heil EL, Hickey C, Klatt M, Kline EG, Kubat RC, Kufel WD, Lee JH, Lim A, Lingg T, MacDougall C, Mathers A, McCreary EK, Moore WJ, Olson S, Oxer J, Pearson JC, Pham C, Polk C, Satlin MJ, Satola SW, Shah S, Solanki YB, Tamma P, Vega A, Venugopalan V, Veve M, Wangchinda W, Witt LS, Wu J, Pogue JM. A multicenter, observational study to compare the effectiveness of CeftazidimeAvibactam versus Ceftolozane-Tazobactam for multidrugresistant Pseudomonas aeruginosa infections in the United States (CACTUS). Platform presentation at IDWeek 2023. Boston, MA.

• Brochu JM, Kenney RM, Herbin S, Gunaga S, Veve MP. Risk Factors for Unplanned Healthcare Encounters in Patients Discharged from the Emergency Department with Extended-spectrum β-lactamase Urinary Tract Infections. Abstract #2843 at IDWeek 2023. Boston, MA.

• CJ Arena, Kenney RM, Eriksson E, Brar I, Veve MP. Impact of Social Determinants of Health on Preferred Treatment of Trichomonas vaginalis and Chlamydia trachomatis. Abstract #1824 at IDWeek 17. 2023. Boston, MA.

• Hardy ME, Kenney RM, Tibbetts R, Shallal A, Veve MP. Leveraging Stewardship to Promote Narrower spectrum Antibiotic Use for Low-risk AmpC Enterobacterales. Platform presentation at IDWeek 2023. Boston, MA.

• Shallal A, Veve MP, Kenney RM, Alangaden GA, Suleyman G. Antimicrobial Therapy and Outcomes of New Delhi Metallo-B-Lactamase (NDM)-Producing Escherichia coli: A Case Series. Abstract #P3284 at the 2023 ECCMID in Copenhagen, Denmark.

• Scribner R, Davis SL, Veve MP. Antibiotic Appropriateness and Social Determinants of Health in Pelvic Inflammatory Disease. Abstract #P1340 at the 2023 ECCMID in Copenhagen, Denmark.

• Kunz Coyne AJ, Lucas K, Witucki P, Orzol C, Bleick C, Truong J, Andrade J, Cerenzio J, Biagi M, Todd M, Veve MP, Rybak MJ. Early Administration of Ceftazidime-Avibactam for MDR-P. aeruginosa Pneumonia Increases Clinical Success Rates. Abstract at the 2023 ECCMID in Copenhagen, Denmark.

• Ho TA, Patterson KM, Kenney RM, Veve MP. Duration of Antibiotic Therapy in Ambulatory Oncology Settings: is Short Course Therapy as Good as Long? Abstract #P2394 at the 2023 ECCMID in Copenhagen, Denmark.

• Hardy ME, Langley CJ, Aljundi AM, Dierker MS, Kenney RM, Veve MP. Quantifying Antimycobacterial Treatment-Related Harms Among Patients with Non-Tuberculosis Mycobacterium Infections: An Opportunity for Novel Agents? Abstract #P1068 at the 2023 ECCMID in Copenhagen, Denmark.

• Fronrath M, Griebe K, Martz C, Veve MP, Smith ZR. Safety and efficacy of cefepime intravenous push vs. piggyback in Gram-negative bacteremia. Society of Critical Care Medicine Annual Meeting. 2023. Abstract# 438. San Francisco, CA.

Courses taught by Michael Veve, PharmD, MPH

Winter Term 2025 (future)

• PHA5215 - Principles of Pharmacotherapy IV: Infectious Diseases

Winter Term 2024

• PHA5215 - Principles of Pharmacotherapy IV: Infectious Diseases

Spring-Summer Term 2023

• PHA5215 - Principles of Pharmacotherapy IV: Infectious Diseases

Winter Term 2023

• PHA5215 - Principles of Pharmacotherapy IV: Infectious Diseases

Winter Term 2022

• PHA5215 - Principles of Pharmacotherapy IV: Infectious Diseases

← Return to listing